Form D · Biotechnology
Starling Medical, Inc.
Houston, TX · CIK 0002031505
Offering snapshot reported Mar 19, 2026 · SEC filing
- Reported sold
- $825K Offering amount: $1.75M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 27, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 19, 2026 | Initial | $824,990 | No comparison | 5 | SEC filing |
| Dec 9, 2024 | Amendment | $8,890,606 | $2,139,995vs Sep 18, 2024 | 40 | SEC filing |
| Sep 18, 2024 | Initial | $6,750,611 | No comparison | 37 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-577063
Source: Form D, filed Mar 19, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shana Barghouti | Director |
| William Hagaman | Director |
| William Andrew Hendricks | Director |
| Hannah Mc Kenney | Director, Executive |
| Kunj Sheth | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2450 Holcombe Boulevard Suite 1320
Houston, TX, 77021
Houston, TX, 77021